The following gastrointestinal agent is contraindicated in pregnancy: (1)1.        Calcium carbonate2.        Famotidine3.        Lansoprazole4.        Misoprostol5.        Docusate

The following drug should not be administered in an asthmatic patient with atrial fibrillation: (1)1.       Theophylline2.       Ciclesonide3.       Montelukast4.       Mometasone furoate5.       Terbutaline sulphate

The following are therapeutic uses of topiramate except: (1)1.        Generalised tonic-clonic seizures2.        Focal seizures3.        Lennox-Gastaut syndrome4.        Prophylaxis for migraines5.        Parkinson’s disease

The following agent is not recommended for patients with genetically low levels of glucose-6-phosphate dehydrogenase (G6PD): (1)1.        Primaquine2.        Mefloquine3.        Quinine4.        Chloroquine5.        Pyrimethamine

The following drug is a dipeptidyl peptidase IV inhibitor: (1)1.        Metformin2.        Glibenclamide3.        Repaglinide 4.        Sitagliptin5.        Insulin

The following can be used in the treatment of gout: (1)1.        Azathioprine2.        Allopurinol3.        Tacrolimus4.        Furosemide5.        Rifampicin

Montelukast has the following indication: (1)1.        Prophylaxis for asthma2.        Antitussive 3.        Maintenance of chronic obstructive pulmonary disease4.        Croup5.        Nasal congestion

The following is true regarding a cell membrane: (1)1.        Consists of an uninterrupted non-polar section only2.        Majority of the membrane is non-polar in nature3.        Aqueous channels allow non-polar drug to enter the cell4.        The polar membrane is interrupted with aqueous channels5.        Slit junctions form the major part

The following drug can be used for prevention of P. falciparum malaria during pregnancy: (1)1.        Atovaquone-proguanil2.        Metronidazole3.        Doxycycline4.        Mefloquine5.        Quinine

The following is correct concerning human immunodeficiency virus (HIV) resistance to protease inhibitors: (1)1.        High-level resistance occurs to the reverse transcriptase enzyme.2.        It occurs as an accumulation of stepwise mutations of the protease gene.3.        It occurs to prevent allosteric inhibition of the reverse transcriptase enzyme.4.        Resistance occurs as four specific substitutions of the integrase gene.5.        A single-point mutation occurs within the integrase gene.